Robert Sarrazin

Robert Sarrazin is the Chief Investment Officer and Managing Partner at the Autism Impact Fund, based in New York. He oversees the firm's life sciences practice and helped close a $60 million fund in 2024, deploying capital across twelve portfolio companies including Cortica and SpectrumAi. Previously, he served as Vice President and Global Head of External Innovation and Direct Investments at GlaxoSmithKline Consumer Healthcare, executing over thirty transactions across digital devices, artificial intelligence, and diagnostics. His earlier career includes tenures as a Senior Partner at CSW and sixteen years focusing on healthcare acquisitions at Charter Oak Partners. He holds an MBA as valedictorian from the NYU Stern School of Business and a bachelor's degree from the Richard Ivey School of Business. Sarrazin currently focuses on backing early-stage life sciences startups addressing neurodevelopmental disorders and complex chronic conditions.